Canadian News

Biotech Stocks Awaiting FDA Decision In February

The following are the stocks scheduled for February, with regulatory catalysts.

1. Adamas Pharmaceuticals Inc. (ADMS)

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

More Canadian News